Early-treatment coagulation activation and radiographic progression during VEGF/VEGFR inhibitor therapy: A multicancer real-world cohort study

Coagulation activation is common in cancer, but its link to treatment durability is unclear. We investigated whether early-treatment coagulation activation correlated with radiographic progression during vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitor therapy. This single-center, retrospective, multicancer cohort study developed a coagulation activation score (0-2) based on the last available D-dimer (>500 ng/mL) and fibrinogen (>4.0 g/L) measurements taken within 100 days after baseline. Multivariable Cox models calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for subsequent radiographic time to progression among patients who were progression-free at the 100-day landmark. Of 1400 eligible patients, 1089 had evaluable early-treatment measurements, and 909 were included in the landmark analysis. Compared to a score of 0, adjusted HRs were 1.29 (95% CI 1.02-1.62) for score 1 and 1.51 (95% CI 1.07-2.12) for score 2. Score 2 also correlated with lower odds of durable clinical benefit (adjusted odds ratio 0.56, 95% CI 0.38-0.84), while objective response and best tumor shrinkage did not show a consistent gradient. These associations remained significant in time-dependent and timing-restricted analyses. Exploratory subgroup analyses revealed the strongest association in colorectal cancer patients treated with bevacizumab (score 2 vs. 0: HR 2.23, 95% CI 1.21-4.11); however, no association was observed in lung cancer patients treated with bevacizumab. No significant interaction with documented immune checkpoint inhibitor exposure was detected. The score did not enhance discrimination beyond clinical variables and baseline coagulation markers. Early-treatment coagulation activation was associated with reduced treatment durability during VEGF/VEGFR inhibition. Prospective validation in specific cancer-drug contexts is necessary.

Authors

Publication Details

Journal
Biomolecules and Biomedicine
Published
2026-10-15
DOI
https://doi.org/10.17305/bb.2026.15049
Primary Topic
Angiogenesis and VEGF in Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early-treatment coagulation activation and radiographic progression during VEGF/VEGFR inhibitor therapy: A multicancer real-world cohort study

Tianye Lv, Bai Liu, Sibei Han, Yingda Liu et al.
Biomolecules and Biomedicine
Angiogenesis and VEGF in Cancer
article

Early-treatment coagulation activation and radiographic progression during VEGF/VEGFR inhibitor therapy: A multicancer real-world cohort study

Tianye Lv, Bai Liu, Sibei Han, Yingda Liu, Xin Zhou, Teng Zhang, Su Liu, Huichao Li, Shuo Sun
article en

Abstract

Coagulation activation is common in cancer, but its link to treatment durability is unclear. We investigated whether early-treatment coagulation activation correlated with radiographic progression during vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitor therapy. This single-center, retrospective, multicancer cohort study developed a coagulation activation score (0-2) based on the last available D-dimer (>500 ng/mL) and fibrinogen (>4.0 g/L) measurements taken within 100 days after baseline. Multivariable Cox models calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for subsequent radiographic time to progression among patients who were progression-free at the 100-day landmark. Of 1400 eligible patients, 1089 had evaluable early-treatment measurements, and 909 were included in the landmark analysis. Compared to a score of 0, adjusted HRs were 1.29 (95% CI 1.02-1.62) for score 1 and 1.51 (95% CI 1.07-2.12) for score 2. Score 2 also correlated with lower odds of durable clinical benefit (adjusted odds ratio 0.56, 95% CI 0.38-0.84), while objective response and best tumor shrinkage did not show a consistent gradient. These associations remained significant in time-dependent and timing-restricted analyses. Exploratory subgroup analyses revealed the strongest association in colorectal cancer patients treated with bevacizumab (score 2 vs. 0: HR 2.23, 95% CI 1.21-4.11); however, no association was observed in lung cancer patients treated with bevacizumab. No significant interaction with documented immune checkpoint inhibitor exposure was detected. The score did not enhance discrimination beyond clinical variables and baseline coagulation markers. Early-treatment coagulation activation was associated with reduced treatment durability during VEGF/VEGFR inhibition. Prospective validation in specific cancer-drug contexts is necessary.

Biomolecules and Biomedicine
Good health and well-being
Openalex Percentile: Top 24%
Angiogenesis and VEGF in Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.